Last reviewed · How we verify
ACEI / ARB+finerenone
This combination therapy blocks angiotensin II signaling via ACE inhibitors or ARBs while finerenone acts as a non-steroidal mineralocorticoid receptor antagonist to reduce kidney and cardiovascular injury.
This combination therapy blocks angiotensin II signaling via ACE inhibitors or ARBs while finerenone acts as a non-steroidal mineralocorticoid receptor antagonist to reduce kidney and cardiovascular injury. Used for Chronic kidney disease with hypertension, Diabetic kidney disease.
At a glance
| Generic name | ACEI / ARB+finerenone |
|---|---|
| Sponsor | Capital Institute of Pediatrics, China |
| Drug class | ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination |
| Target | Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Nephrology |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors and ARBs reduce angiotensin II-mediated vasoconstriction and aldosterone release, lowering blood pressure and proteinuria. Finerenone selectively antagonizes the mineralocorticoid receptor in the kidney and cardiovascular tissues, providing additional renoprotection and cardioprotection independent of blood pressure reduction. Together, they address multiple pathways in the renin-angiotensin-aldosterone system (RAAS) to slow chronic kidney disease progression.
Approved indications
- Chronic kidney disease with hypertension
- Diabetic kidney disease
Common side effects
- Hyperkalemia
- Hypotension
- Acute kidney injury
- Dizziness
Key clinical trials
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (PHASE3)
- FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan (PHASE3)
- Rubix LS Diabetic Kidney Disease (DKD) Registry Study
- Finerenone Therapy for Pediatric HSPN With Mild Proteinuria (PHASE4)
- Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study (PHASE2)
- Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACEI / ARB+finerenone CI brief — competitive landscape report
- ACEI / ARB+finerenone updates RSS · CI watch RSS
- Capital Institute of Pediatrics, China portfolio CI